ERBB2 and cancer: The phase II DESTINY-Gastric01 showed significant improvement with T-DXd compared to standard chemotherapy in terms of ORR (51.3 vs. 14.3%) and mOS (12.5 vs. 8.4 months) for patients with heavily pretreated HER2-positive G/GEJ cancers, leading to its approval as second-line therapy [70].